Drug Coated Balloon Catheter Market Size was valued at USD 0.61 Billion in 2022. The Drug Coated Balloon Catheter market industry is projected to grow from USD 0.69 Billion in 2023 to USD 1.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.00% during the forecast period (2024 - 2032). A growing elderly population and the increase in technical advancements and modernization of healthcare equipment are the key market drivers that are boosting the expansion of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for Drug Coated Balloon Catheter supplements is being driven by the rising number of elderly population. A new type of medical equipment called a drug-coated balloon catheter is used to treat restricted blood arteries. It is performed by inserting a catheter and a guide wire into the femoral artery in the leg or the radial artery in the arm. A drug-coated balloon catheter can also be used in a minimally invasive procedure to open coronary arteries that are constricted or occluded due to coronary artery disease (CAD).
Additionally, the demographic shift that is propelling the market's expansion is the aging of the population. In addition, a growing population that is more vulnerable to cardiovascular illnesses and rising healthcare costs are propelling market expansion. Furthermore, the primary driver of the market expansion is the rise in the prevalence of chronic illnesses like diabetes, osteoarthritis, neuropathy, and cancer. Furthermore, favorable reimbursement policies, the launch of increasingly sophisticated therapeutic solutions, and shifting patient demographics are expected to fuel market expansion throughout the course of the projected period. The market expansion is being impeded by the exorbitant cost of these devices and their essential components. Furthermore, the high expense of catheterization treatments may limit market expansion in developing nations with somewhat low-income levels.
Raising market expansion is being created by the increase in healthcare R&D activities, the modernization and technological advancements in medical equipment, the expansion of developing markets, and the growth of these areas. Furthermore, rising citizen healthcare spending and federal government campaigns to promote heart health awareness are expected to fuel market expansion throughout the projected timeframe. The primary strategic efforts that the industry players carry out to promote market expansion throughout the projected period include collaborations, mergers and acquisitions, and the introduction of new products as a result of technical advancements. The high cost of drug-eluting balloon catheterization therapies may be a barrier to company expansion in a low-income growing sector. Additionally, it is anticipated that the high price of cutting-edge medical technologies will restrict market growth.
For instance, peripheral artery disease (PAD) affects over 200 million individuals globally and is linked to elevated rates of death and morbidity, according to the American Heart Association 2021 study. PAD may probably grow more prevalent as the world's population ages. Peripheral drug-eluting balloons are being driven by the faster-growing number of PADs, according to statistics. Thus, result in driving the Drug Coated Balloon Catheter market revenue.
The Drug Coated Balloon Catheter Market segmentation, based on type, includes Paclitaxel and Sirolimus. In 2023, the Paclitaxel segment dominated the market. Modern instruments are being used by more healthcare facilities and medical personnel to carry out intricate interventional treatments. Through their assistance in drug distribution, inhibition of restenosis, and restriction of vascular smooth muscle cell proliferation during neointimal growth and development, peripheral vascular balloon catheters improve patient safety during surgical procedures.
The Drug Coated Balloon Catheter Market segmentation, based on Product, includes Coronary Artery Disease and peripheral Vascular Disease. In 2023, the Peripheral Vascular Disease category generated the most income. Peripheral vascular balloon catheters enhance patient safety during surgical procedures by facilitating the supply of drugs, limiting the proliferation of vascular smooth muscle cells during neointimal development, and preventing restenosis.
The Drug Coated Balloon Catheter Market segmentation, based on End-use, includes Hospital, Clinics, and Ambulatory Surgical Centers. In 2023, the Hospital category generated the most income. This is because the market is expected to grow as a result of a rise in the number of hospital in-patient admissions for catheterization operations and a growing desire for minimally invasive procedures. A few of the factors propelling the market's growth are the rise in urological and vascular conditions, arrhythmia, etc.
Figure1: Drug Coated Balloon Catheter Market, by End-use, 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Drug Coated Balloon Catheter market area will dominate this market, owing to an increased number of factors, including the region's high concentration of highly skilled surgeons and the rising incidence of urological and renal failure, which will boost market growth in this region.
Further, the major countries examined in the market report are China, Japan, India, Australia, South Korea, Germany, France, the UK, Italy, and Spain.
Figure2: Drug Coated Balloon Catheter Market Share By Region 2023 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe Drug Coated Balloon Catheter market has the second-largest portion of the market. This is due to the expansion of medical travel throughout numerous emerging nations. Further, the German Drug Coated Balloon Catheter market possesses the biggest market share, and the UK Drug Coated Balloon Catheter market was the European market with the quickest rate of growth.
The Asia-Pacific Drug Coated Balloon Catheter Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to the rising popularity and accessibility of minimally invasive surgeries. Moreover, China’s Drug Coated Balloon Catheter market possesses the biggest market share, and the Indian Drug Coated Balloon Catheter market was the Asia-Pacific region's fastest-growing market.
Drug Coated Balloon Catheter Key Market Players & Competitive Insights
Leading market players are putting a lot of money into R&D to expand their range of products, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure an increasingly cutthroat and dynamic market, the drug-coated Balloon catheter industry must provide reasonably priced goods.
Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the global drug-coated Balloon catheter industry to help customers and expand the market segment. In recent years, the drug-coated Balloon catheter industry has provided some of the biggest benefits to medicine. Major players in the Drug Coated Balloon Catheter market, including Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, and Boston Scientific Corporation, are engaging in research and development activities in an effort to boost market demand.
Founded in Delaware, Boston Scientific Corporation ("BSC") is a multinational biomedical/biotechnology engineering company that specializes in the production of medical devices for use in a variety of interventional medical specialties, such as peripheral actions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. The Tax Us Stent is a drug-eluting stent that is used to unblock clogged arteries, and Boston Scientific is well-known for creating it. In January 2021, Boston declared that it would pay up to $1.2 billion to acquire Minneapolis-based Preventice Solutions, Inc. and its suite of mobile heart health solutions.
Medtronic plc is a US-based medical device manufacturer. The company now has its operational, executive, and legal headquarters in Minneapolis, Minnesota, and its operating headquarters in Ireland as a result of its 2015 acquisition of the Irish company Covidien. It employs approximately 90,000 people and conducts business in more than 150 countries, with the United States being its primary market. It creates and produces medical devices and treatments. In October 2022, The Company said that it intended to pursue the separation of its Medical-Surgical Portfolio businesses, which include the combined Patient Monitoring and Respiratory Interventions businesses.
Key Companies in the Drug Coated Balloon Catheter market include
March 2023: After receiving CE approval, Boston Scientific's Farapulse device became the only PFA catheter technology to be commercially sold for the treatment of atrial fibrillation (AF), which affects about 60 million people worldwide.
May 2023: A private placement round raised USD 65 million for Pulse Biosciences. Pulse Biosciences executive chairman Robert W. Duggan led the round. The company's exclusive Nanosecond Pulsed Field AblationTM (nsPFATM) technology for the treatment of atrial fibrillation will be developed with the funds raised from the round.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 0.61 Billion |
| Market Size 2023 | USD 0.69 Billion |
| Market Size 2032 | USD 1.7 Billion |
| Compound Annual Growth Rate (CAGR) | 12.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Product, End-use, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | China, Japan, India, Australia, South Korea, Germany, France, UK, Italy, and Spain |
| Key Companies Profiled | Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, Boston Scientific Corporation |
| Key Market Opportunities | · A growing elderly population |
| Key Market Dynamics | · The increase in technical advancements and healthcare equipment modernization |
Frequently Asked Questions (FAQ) :
In 2023, the market for Drug Coated Balloon Catheter was estimated to be worth USD 0.69 billion worldwide.
From 2024 to 2032, It is anticipated that the worldwide market will rise at a CAGR of 12.00%.
North America held the most market share worldwide.
The key companies in the market are Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, and Boston Scientific Corporation, among others.
In 2023, the market was dominated by the Hospital sector.
Peripheral vascular disease holds the biggest market share worldwide.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
